Ibsrela, a drug developed by Edinburgh-based pharmaceutical company Aptalis Pharma, received U.S. Food and Drug Administration (FDA) approval on December 22, 2014. It is indicated for the treatment of patients with hepatic encephalopathy (HE) who are not able to tolerate or achieve adequate seizure control with lactulose. Specifically, Ibsrela is approved for patients with a Grade 1-4 HE, who are in grades 1-4, to reduce blood ammonia levels by reducing the production of ammonia in the gut. The drug's active ingredient is rifaximin, which is also the active ingredient in Xifaxan, another drug approved by the FDA [1].
How does Ibsrela work to lower ammonia levels?
Ibsrela, containing the active ingredient rifaximin, works by targeting the gut bacteria responsible for producing ammonia. Rifaximin is a non-absorbable antibiotic that acts locally within the gastrointestinal tract [1]. It reduces the proliferation of ammonia-producing bacteria in the gut, thereby decreasing the amount of ammonia absorbed into the bloodstream and potentially helping to manage hepatic encephalopathy [1][2].
What is Hepatic Encephalopathy (HE)?
Hepatic encephalopathy (HE) is a serious complication of liver disease that affects brain function. It occurs when the liver is unable to adequately filter toxins from the blood, leading to a buildup of these substances, such as ammonia. This buildup can cause a range of neurological symptoms, from mild confusion and personality changes to severe disorientation, coma, and even death. HE is often seen in individuals with cirrhosis or other forms of advanced liver disease [3].
How does Ibsrela compare to other HE treatments like lactulose?
Ibsrela is indicated for patients with hepatic encephalopathy who cannot tolerate lactulose or do not achieve adequate seizure control with it [1]. Lactulose is a laxative that works by drawing water into the intestines, which helps to flush out ammonia and prevent its absorption. While effective for many, some patients experience side effects like bloating, gas, and diarrhea with lactulose, or find it insufficient for managing their HE symptoms. Ibsrela offers an alternative for these individuals [1][2].
When does Ibsrela's patent protection expire?
Information regarding the specific patent expiry dates for Ibsrela is not publicly available in the provided context. Drug patent information can be complex, often involving multiple patents for a single drug, including composition of matter patents, method of use patents, and formulation patents. Resources like DrugPatentWatch.com track and provide detailed information on drug patent statuses and expiration dates for pharmaceutical products [4].
What are the potential side effects of Ibsrela?
The most common side effects associated with Ibsrela include nausea and vomiting [1]. Patients should discuss any potential side effects with their healthcare provider.
Can Ibsrela be used for other conditions?
Rifaximin, the active ingredient in Ibsrela, is also approved under the brand name Xifaxan for other indications, including the treatment of traveler's diarrhea caused by E. coli and for the reduction of risk of overt hepatic encephalopathy recurrence in patients 18 years of age and older who have had overt hepatic encephalopathy [1]. However, the specific indication for Ibsrela is for patients with HE who are not candidates for lactulose [1].
---
Sources
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206187s000lbl.pdf
[2] https://www.drugpatentwatch.com/drug/ibsrela
[3] https://www.niddk.nih.gov/health-information/liver-disease/hepatic-encephalopathy
[4] https://www.drugpatentwatch.com/